CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CBAY
  • CUSIP: N/A
  • Web: www.cymabay.com
Capitalization:
  • Market Cap: $273.04 million
  • Outstanding Shares: 28,752,000
Average Prices:
  • 50 Day Moving Avg: $6.60
  • 200 Day Moving Avg: $4.50
  • 52 Week Range: $1.15 - $8.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.45
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.79 million
  • Price / Sales: 37.46
  • Book Value: $0.07 per share
  • Price / Book: 89.14
Profitability:
  • EBIDTA: ($20,290,000.00)
  • Return on Equity: -425.44%
  • Return on Assets: -122.91%
Debt:
  • Debt-to-Equity Ratio: 2.15%
  • Current Ratio: 1.49%
  • Quick Ratio: 1.49%
Misc:
  • Average Volume: 1.04 million shs.
  • Beta: 2.11
  • Short Ratio: 1.72
 

Frequently Asked Questions for CymaBay Therapeutics (NASDAQ:CBAY)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc. (NASDAQ:CBAY) released its earnings results on Thursday, August, 10th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.06. View CymaBay Therapeutics' Earnings History.

When will CymaBay Therapeutics make its next earnings announcement?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for CymaBay Therapeutics.

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?

6 brokers have issued 1-year target prices for CymaBay Therapeutics' stock. Their predictions range from $12.00 to $15.00. On average, they anticipate CymaBay Therapeutics' share price to reach $13.80 in the next year. View Analyst Ratings for CymaBay Therapeutics.

What are analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (4/3/2017)
  • 2. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
  • 3. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totalling 1,076,152 shares, an increase of 75.9% from the July 14th total of 611,816 shares. Based on an average daily volume of 3,069,062 shares, the short-interest ratio is presently 0.4 days. Currently, 2.7% of the shares of the company are short sold.

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:

  • Robert James Wills Ph.D., Chairman of the Board
  • Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
  • Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
  • Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
  • Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
  • Pol F. Boudes M.D., Chief Medical Officer
  • Robert Booth Ph.D., Director
  • Caroline Loewy, Director
  • Evan A. Stein M.D. Ph.D., Director
  • Paul F. Truex, Director

Who owns CymaBay Therapeutics stock?

CymaBay Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Versant Venture Management LLC (3.65%), Vanguard Group Inc. (3.45%), Omega Fund Management LLC (1.05%), Northern Trust Corp (0.18%), Marshall Wace North America L.P. (0.14%) and Alpha Cubed Investments LLC (0.07%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. View Insider Buying and Selling for CymaBay Therapeutics.

Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Marshall Wace North America L.P., LVM Capital Management Ltd. MI and Bank of New York Mellon Corp. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $6.24.


MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.80 (121.15% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Ifs SecuritiesDowngradeStrong-Buy -> OutperformHighView Rating Details
7/25/2017Piper Jaffray CompaniesReiterated RatingPositive -> Overweight$12.00LowView Rating Details
7/20/2017CIBCReiterated RatingOutperform -> Outperform$8.00 -> $15.00MediumView Rating Details
7/20/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$8.00 -> $15.00MediumView Rating Details
7/20/2017Citigroup Inc.Reiterated RatingOutperform$8.00 -> $15.00MediumView Rating Details
7/17/2017HC WainwrightBoost Price TargetBuy$7.00 -> $12.00HighView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings History by Quarter for CymaBay Therapeutics (NASDAQ CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
8/10/2017Q2 2017($0.25)($0.31)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.27)($0.20)$4.79 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.28)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.31)($0.25)ViewListenView Earnings Details
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/11/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015Q1 2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.46)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.48)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
2017 EPS Consensus Estimate: ($0.81)
2018 EPS Consensus Estimate: $0.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.28)($0.28)($0.28)
Q2 20172($0.29)($0.25)($0.27)
Q3 20172($0.20)($0.14)($0.17)
Q4 20172($0.21)$0.03($0.09)
Q1 20181($0.28)($0.28)($0.28)
Q2 20181$0.48$0.48$0.48
Q3 20181$0.35$0.35$0.35
Q4 20181($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 25.39%
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2017Robert James WillsDirectorBuy5,000$6.84$34,200.00View SEC Filing  
7/20/2017Charles McwherterSVPBuy5,000$7.43$37,150.00View SEC Filing  
7/20/2017Sujal ShahInsiderBuy10,000$7.34$73,400.00View SEC Filing  
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.00View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CymaBay Therapeutics (NASDAQ:CBAY)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
Source:
DateHeadline
streetinsider.com logoCymaBay Therapeutics (CBAY) Announces the Publication of ... - StreetInsider.com
www.streetinsider.com - August 16 at 5:29 PM
finance.yahoo.com logoCymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology
finance.yahoo.com - August 15 at 5:43 PM
americanbankingnews.com logoAnalysts Offer Predictions for CymaBay Therapeutics Inc.'s Q4 2017 Earnings (NASDAQ:CBAY)
www.americanbankingnews.com - August 14 at 6:42 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (CBAY) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 14 at 2:44 AM
americanbankingnews.com logoShort Interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) Increases By 75.9%
www.americanbankingnews.com - August 13 at 1:46 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (NASDAQ:CBAY) Downgraded by Ifs Securities to Outperform
www.americanbankingnews.com - August 11 at 1:26 PM
americanbankingnews.com logoCymaBay Therapeutics Inc. (CBAY) Announces Earnings Results
www.americanbankingnews.com - August 10 at 9:34 PM
nasdaq.com logoAfter-Hours Earnings Report for August 10, 2017 : NVDA, JWN, PBR, NWSA, AZPN, AVXS, PCTY, LXFT, EPAY, NH ... - Nasdaq
www.nasdaq.com - August 10 at 6:07 PM
finance.yahoo.com logoWhy CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season - Yahoo Finance
finance.yahoo.com - August 10 at 6:07 PM
finance.yahoo.com logoCymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:07 PM
nasdaq.com logoWhy CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - August 9 at 10:11 PM
finance.yahoo.com logoWhy CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season
finance.yahoo.com - August 9 at 5:08 PM
americanbankingnews.com logoCymaBay Therapeutics Inc. (CBAY) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - August 9 at 7:46 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (CBAY) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 8 at 10:44 AM
americanbankingnews.com logoHead to Head Review: CymaBay Therapeutics (NASDAQ:CBAY) versus REGENXBIO (RGNX)
www.americanbankingnews.com - August 8 at 8:30 AM
globenewswire.com logoCymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10 - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:27 PM
finance.yahoo.com logoCymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10
finance.yahoo.com - August 7 at 5:26 PM
americanbankingnews.com logoCymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Robert James Wills Purchases 5,000 Shares
www.americanbankingnews.com - August 2 at 10:28 AM
globenewswire.com logoCymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to ... - GlobeNewswire (press release)
globenewswire.com - July 24 at 4:30 PM
finance.yahoo.com logoCymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - July 24 at 4:30 PM
americanbankingnews.com logoCharles Mcwherter Buys 5,000 Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) Stock
www.americanbankingnews.com - July 24 at 9:11 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (CBAY) Insider Acquires $73,400.00 in Stock
www.americanbankingnews.com - July 24 at 9:11 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for CymaBay Therapeutics Inc. Raised by Analyst (CBAY)
www.americanbankingnews.com - July 24 at 7:42 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for CymaBay Therapeutics Inc.'s Q4 2017 Earnings (NASDAQ:CBAY)
www.americanbankingnews.com - July 21 at 1:19 PM
americanbankingnews.com logoCitigroup Inc. Reiterates Outperform Rating for CymaBay Therapeutics Inc. (CBAY)
www.americanbankingnews.com - July 20 at 8:23 PM
americanbankingnews.com logoCIBC Reaffirms Outperform Rating for CymaBay Therapeutics Inc. (NASDAQ:CBAY)
www.americanbankingnews.com - July 20 at 7:08 PM
nasdaq.com logoCymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2% - Nasdaq
www.nasdaq.com - July 20 at 6:41 PM
finance.yahoo.com logoCymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%
finance.yahoo.com - July 20 at 6:41 PM
americanbankingnews.com logoCymaBay Therapeutics Inc. (NASDAQ:CBAY) PT Raised to $15.00 at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 20 at 10:50 AM
americanbankingnews.com logo Analysts Anticipate CymaBay Therapeutics Inc. (NASDAQ:CBAY) Will Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 20 at 9:14 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (NASDAQ:CBAY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 20 at 9:06 AM
americanbankingnews.com logoCymaBay Therapeutics Inc. (NASDAQ:CBAY) Stock Rating Reaffirmed by Ifs Securities
www.americanbankingnews.com - July 20 at 7:50 AM
finance.yahoo.com logoOppenheimer Bullish on Bank of America Corp (BAC), CymaBay Therapeutics Inc (CBAY) and TherapeuticsMD Inc (TXMD); Here’s Why
finance.yahoo.com - July 19 at 6:05 PM
finance.yahoo.com logoCymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
finance.yahoo.com - July 19 at 4:31 AM
finance.yahoo.com logoH.C. Wainwright Boosts Price Target on CymaBay Therapeutics Inc (CBAY)
finance.yahoo.com - July 19 at 4:31 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics
finance.yahoo.com - July 18 at 6:28 PM
streetinsider.com logoAfter-Hours Stock Movers 07/17: (NFLX) (PBYI) (NVAX) Higher; (CBAY) (REI) (SCSS) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 17 at 10:22 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Announces 10M Share Common Offering - StreetInsider.com
www.streetinsider.com - July 17 at 10:22 PM
benzinga.com logoMid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide - Benzinga
www.benzinga.com - July 17 at 5:22 PM
nasdaq.com logoHealth Care Sector Update for 07/17/2017: CBAY,ACRX,RPRX - Nasdaq
www.nasdaq.com - July 17 at 5:22 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Reports Interim Results Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients ... - StreetInsider.com
www.streetinsider.com - July 17 at 5:22 PM
nasdaq.com logoImplied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options - Nasdaq
www.nasdaq.com - July 13 at 8:50 PM
finance.yahoo.com logoImplied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options
finance.yahoo.com - July 13 at 3:41 PM
nasdaq.com logoNew Analyst Coverage Make These 5 Stocks Worth a Bet - Nasdaq
www.nasdaq.com - July 3 at 10:15 PM
finance.yahoo.com logoNew Analyst Coverage Make These 5 Stocks Worth a Bet
finance.yahoo.com - July 3 at 5:00 PM
americanbankingnews.com logoShort Interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) Decreases By 32.6%
www.americanbankingnews.com - July 1 at 7:06 AM
finance.yahoo.com logoPenny Stocks to Watch for July 2017
finance.yahoo.com - June 30 at 5:06 PM
nasdaq.com logoCymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality ... - Nasdaq
www.nasdaq.com - June 27 at 9:26 PM
finance.yahoo.com logoCymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
finance.yahoo.com - June 26 at 4:48 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for CymaBay Therapeutics Inc. Issued By Oppenheimer Holdings (CBAY)
www.americanbankingnews.com - June 26 at 7:08 AM

Social

Chart

CymaBay Therapeutics (CBAY) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff